Despite the challenges posed by the immunosuppressive tumor microenvironment, therapies such as programmed cell death 1 (PD-1) checkpoint inhibitors and chimeric antigen receptor-T (CAR-T) cells are under investigation. Here, PDCD1 is linked to neoplasm.